Lenalidomide in chronic lymphocytic leukemia

References

• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333(16):1052–1057.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang S, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the united states, 1992-2001. Blood. 2006;107(1):265–276.
   PubMed Web of Science ®Google Scholar
• Mauro FR, Foa R, Giannarelli D, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood. 1999;94(2):448–454.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2013. Bethesda (MD): National Cancer Institute. [ cited 2016 Apr]. November 2015 SEER data submission, posted to the SEER web site. Available from: http://seer.cancer.gov/csr/1975_2013/.
   Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–234.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Wierda WG, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. JNCCN. 2015;13(3):326–362.
   Web of Science ®Google Scholar
• Stilgenbauer S. Prognostic markers and standard management of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2015;2015(1):368–377.
   PubMedGoogle Scholar
• Mertens D, Stilgenbauer S. Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches? J Clin Oncol. 2014;32(9):869–872.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Raca G, Wang YL. Predicting prognosis in chronic lymphocytic leukemia in the contemporary era. JAMA Oncol. 2015;1(7):965–974.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Mertens D, Stilgenbauer S. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide. Expert Opin Pharmacother. 2011;12(18):2857–2864.
   PubMed Web of Science ®Google Scholar
• Maffei R, Colaci E, Fiorcari S, et al. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2016;97:291–302.
   PubMed Web of Science ®Google Scholar
• Desai M, Newberry K, Ou Z, et al. Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther Adv Hematol. 2014;5(3):91–101.
   PubMedGoogle Scholar
• Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15(12):1311–1318.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373(19):1835–1844.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Nowakowski GS, Habermann TM, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol. 2015;26(8):1667–1677.
   PubMed Web of Science ®Google Scholar
• FDA approval for lenalidomide. National Cancer Institute. [ cited 2013 Jun 5]. Available from: http://www.cancer.gov/about-cancer/treatment/drug/fda-lenalidomide.
   Google Scholar
• Zeldis JB, Knight R, Hussein M, et al. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann N Y Acad Sci. 2011;1222:76–82.
   PubMed Web of Science ®Google Scholar
• Galanina N, Petrich A, Nabhan C. The evolving role of lenalidomide in non-Hodgkin lymphoma. Leuk Lymphoma. 2016;57(7):1507–1516.
   Google Scholar
• Seiffert M. Lenalidomide, an antiproliferative CLL drug. Blood. 2014;124(10):1545–1546.
   PubMed Web of Science ®Google Scholar
• Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP, et al. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int. 2014;2014:265840.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wen S, et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011;118(13):3489–3498.
   PubMed Web of Science ®Google Scholar
• Brown JR. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong? Leuk Lymphoma. 2010;51(8):1382–1385.
   PubMed Web of Science ®Google Scholar
• Carballido E, Veliz M, Komrokji R, et al. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control. 2012;19(1):54–67.
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Sciumè M, Reda G. Lenalidomide in the treatment of chronic lymphocytic leukemia. Adv Hematol. 2012;2012:1–7.
   Google Scholar
• Gentile M, Recchia AG, Vigna E, et al. Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2011;20(2):273–286.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90(5):446–460.
   PubMed Web of Science ®Google Scholar
• Kater AP, Tonino SH, Egle A, et al. How does lenalidomide target the chronic lymphocytic leukemia microenvironment? Blood. 2014;124(14):2184–2189.
   PubMed Web of Science ®Google Scholar
• Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24(Suppl 1):S13–S19.
   PubMed Web of Science ®Google Scholar
• Fecteau J-F, Corral LG, Ghia EM, et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014;124(10):1637–1644.
   PubMed Web of Science ®Google Scholar
• Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126(21):2366–2369.
   PubMed Web of Science ®Google Scholar
• Anonymous. National center for biotechnology information [Internet]. PubChem Compoound Database; CID=216326. [cited 2016 Apr 15]. Available from: https://pubchem.ncbi.ncbi.nih.gov/compound/216326.
   Google Scholar
• Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
   PubMed Web of Science ®Google Scholar
• Chen N, Wen L, Lau H, et al. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol. 2012;69(3):789–797.
   PubMed Web of Science ®Google Scholar
• Kumar G, Lau H, Laskin O. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction. Cancer Chemother Pharmacol. 2009;63(6):1171–1175.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9):2943–2950.
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163(1):380–386.
   PubMed Web of Science ®Google Scholar
• Marriott JB, Clarke IA, Dredge K, et al. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol. 2002;130(1):75–84.
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103(5):1787–1790.
   PubMed Web of Science ®Google Scholar
• Görgün G, Holderried TAW, Zahrieh D, et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7):1797–1805.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427–2437.
   PubMed Web of Science ®Google Scholar
• Jamroziak K, Szemraj J, Robak T, et al. Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen. Leuk Lymphoma. 2015;56(3):808–810.
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326–2335.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164(6):811–821.
   PubMed Web of Science ®Google Scholar
• Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305–309.
   PubMed Web of Science ®Google Scholar
• Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301–305.
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67(2):746–755.
   PubMed Web of Science ®Google Scholar
• Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma. 2010;51(1):85–88.
   PubMed Web of Science ®Google Scholar
• Arumainathan A, Kalakonda N, Pettitt AR. Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p. Eur J Haematol. 2011;87(4):372–375.
   PubMed Web of Science ®Google Scholar
• Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica. 2009;94(9):1266–1273.
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 2010;115(13):2619–2629.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Clear AJ, Fatah R, et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120(7):1412–1421.
   PubMed Web of Science ®Google Scholar
• Fiorcari S, Martinelli S, Bulgarelli J, et al. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. Haematologica. 2015;100(2):253–262.
   PubMed Web of Science ®Google Scholar
• Jones JA, Byrd J. How will B-cell-receptor-targeted therapies change future CLL therapy? Blood. 2014;123(10):1455–1460.
   PubMed Web of Science ®Google Scholar
• Lee BN, Gao H, Cohen EN, et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011;117(17):3999–4008.
   PubMed Web of Science ®Google Scholar
• Henry JY, Labarthe MC, Meyer B, et al. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs(R) immunomodulatory compounds lenalidomide and pomalidomide. Immunology. 2013;139(3):377–385.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24(34):5343–5349.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee B-N, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111(11):5291–5297.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Hallek M, Fraser GA, et al. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016;57(6):1–9.
   PubMed Web of Science ®Google Scholar
• Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2013;31(5):584–591.
   PubMed Web of Science ®Google Scholar
• Maddocks K, Wei L, Rozewski D, et al. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). Am J Hematol. 2015;90(4):327–333.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Fanning SR, Stephenson J Jr., et al. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015;56(3):645–649.
   PubMed Web of Science ®Google Scholar
• Vitale C, Falchi L, Ten Hacken E, et al. Ofatumumab and lenalidomide for patients with relapsed or refractory chronic lymphocytic leukemia: correlation between responses and immune characteristics. Clin Cancer Res. 2016;22(10):2359–2367.
   PubMed Web of Science ®Google Scholar
• Chen CI, Bergsagel PL, Paul H, et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol. 2011;29(9):1175–1181.
   PubMed Web of Science ®Google Scholar
• Brown JR, Abramson J, Hochberg E, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia. 2010;24(11):1972–1975.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Cooper RS, Thompson DS, et al. Fludarabine, rituximab, and lenalidomide in previously untreated patients with chronic lymphocytic leukemia (CLL): a phase I/II trial of the Sarah Cannon Research Institute. Blood. 2012;120(21):715.
   Web of Science ®Google Scholar
• Egle A, Steurer M, Gassner FJ, et al. Lenalidomide/rituximab maintenance after induction with fludarabine/rituximab in combination with escalating doses of lenalidomide in previously untreated chronic lymphocytic leukemia (CLL): the revlirit CLL5 AGMT phase I/II study, final results. Blood. 2013;122(21):4164.
   Google Scholar
• James DF, Werner L, Brown JR, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol. 2014;32(19):2067–2073.
   PubMed Web of Science ®Google Scholar
• Chen CI, Paul H, Snitzler S, et al. A phase 2 study of lenalidomide in combination with oral dexamethasone in previously untreated, symptomatic patients with chronic lymphocytic leukemia (CLL). Blood. 2015;126(23):4163.
   Google Scholar
• Thompson PA, Keating MJ, Hinojosa C, et al. Lenalidomide and rituximab in combination as initial treatment of chronic lymphocytic leukemia: initial results of a phase II study. Blood. 2014;124(21):1988.
   Google Scholar
• Chen CI, Paul H, Wang T, et al. Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia. Br J Haematol. 2014;165(5):731–733.
   PubMed Web of Science ®Google Scholar
• Strati P, Keating MJ, Wierda WG, et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013;122(5):734–737.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011;117(10):2127–2135.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Hillmen P, Mahadevan D, et al. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(3):417–423.
   PubMed Web of Science ®Google Scholar
• Egle A, Gassner F, Geisberger R, et al. A combination of fludarabine/rituximab with escalating doses of lenalidomide in untreated chronic lymphocytic leukemia: the REVLIRIT CLL5 AGMT phase 1/2 study—results from clinical and exploratory analyses of induction results. Blood. 2011;118(21):292.
   Google Scholar
• Shanafelt TD, Ramsay AG, Zent CS, et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 2013;121(20):4137–4141.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rodriguez AP, Payer AR, Acebes-Huerta A, et al. Lenalidomide and chronic lymphocytic leukemia. Biomed Res Int. 2013;2013:932010.
   PubMed Web of Science ®Google Scholar
• Aue G, Nelson Lozier J, Tian X, et al. Inflammation, TNFalpha and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. Am J Hematol. 2011;86(10):835–840.
   PubMed Web of Science ®Google Scholar
• Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26(15):2519–2525.
   PubMed Web of Science ®Google Scholar
• Moutouh-de Parseval LA, Weiss L, DeLap RJ, et al. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol. 2007;25(31):5047.
   PubMed Web of Science ®Google Scholar
• Maddocks K, Ruppert AS, Browning R, et al. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leuk Res. 2014;38(9):1025–1029.
   PubMed Web of Science ®Google Scholar
• Georg Aue SS, Janet V, Diane C. Arthur, Xin Tian5* and Adrian Wiestner. Phase II trial of pulse dosed lenalidomide in previously treated chronic lymphocytic leukemia. Blood. 2010;116(21):1383–83.
   Web of Science ®Google Scholar
• Lamanna N. New oral small molecules in the treatment of chronic lymphocytic leukemia. Cancer. 2015;121(12):1917–1926.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Jones JJ, Woyach JA, et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol. 2014;32(27):3039–3047.
   PubMed Web of Science ®Google Scholar
• Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2012;2012:88–96.
   PubMedGoogle Scholar
• Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12(3):229–243.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Coutre S, Gore L, et al. A dose escalation study of ibrutinib with lenalidomide for relapsed and refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood. 2014;124(21):1987.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Nastoupil LJ, Neelapu SS, et al. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015;125(21):3357–3359.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, De Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.
   PubMed Web of Science ®Google Scholar
• Keating GM. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin’s lymphoma. Target Oncol. 2015;10(1):141–151.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013;122(11):1891–1899.
   PubMed Web of Science ®Google Scholar